Terms: = Germ cell tumor AND RHOA, ENSG00000067560, 387, ARHA, RhoA, RHOH12, RHO12, ARH12, Rho12
373 results:
1. Development and validation of a novel model to predict recurrence-free survival and melanoma-specific survival after sentinel lymph node biopsy in patients with melanoma: an international, retrospective, multicentre analysis.
Stassen RC; Maas CCHM; van der Veldt AAM; Lo SN; Saw RPM; Varey AHR; Scolyer RA; Long GV; Thompson JF; Rutkowski P; Keilholz U; van Akkooi ACJ; Verhoef C; van Klaveren D; Grünhagen DJ
Lancet Oncol; 2024 Apr; 25(4):509-517. PubMed ID: 38547894
[TBL] [Abstract] [Full Text] [Related]
2. A combined opposite targeting of p110δ PI3K and rhoa abrogates skin cancer.
Tzenaki N; Xenou L; Goulielmaki E; Tsapara A; Voudouri I; Antoniou A; Valianatos G; Tzardi M; De Bree E; Berdiaki A; Makrigiannakis A; Papakonstanti EA
Commun Biol; 2024 Jan; 7(1):26. PubMed ID: 38182748
[TBL] [Abstract] [Full Text] [Related]
3. Elucidation of GPR55-Associated Signaling behind THC and LPI Reducing Effects on Ki67-Immunoreactive Nuclei in Patient-Derived Glioblastoma cells.
Kolbe MR; Hohmann T; Hohmann U; Maronde E; Golbik R; Prell J; Illert J; Strauss C; Dehghani F
Cells; 2023 Nov; 12(22):. PubMed ID: 37998380
[TBL] [Abstract] [Full Text] [Related]
4. Identification of hub gene and lncRNA signature related to entotic cell death in cutaneous melanoma for prognostic and immune prediction.
Zhang C; Shen C
Medicine (Baltimore); 2023 Nov; 102(45):e35881. PubMed ID: 37960805
[TBL] [Abstract] [Full Text] [Related]
5. Oncogenic Gαq activates RhoJ through PDZ-RhoGEF.
Cervantes-Villagrana RD; Color-Aparicio VM; Castillo-Kauil A; García-Jiménez I; Beltrán-Navarro YM; Reyes-Cruz G; Vázquez-Prado J
Int J Mol Sci; 2023 Oct; 24(21):. PubMed ID: 37958718
[TBL] [Abstract] [Full Text] [Related]
6. Impact of primary tumor resection and metastasectomy among gastroentero-pancreatic neuroendocrine tumors with liver metastases only on survival.
Chen Q; Li K; Rhodin KE; Bartholomew AJ; Lidsky ME; Wei Q; Cai J; Luo S; Zhao H
HPB (Oxford); 2024 Jan; 26(1):125-136. PubMed ID: 37806829
[TBL] [Abstract] [Full Text] [Related]
7. Identification of immune-related hub genes and construction of an immune-related gene prognostic index for low-grade glioma.
Zhou J; Guo H; Liu L; Jin Z; Zhang W; Tang T
J Cell Mol Med; 2023 Dec; 27(23):3851-3863. PubMed ID: 37775993
[TBL] [Abstract] [Full Text] [Related]
8. Scoparone attenuates glioma progression and improves the toxicity of temozolomide by suppressing rhoa/ROCK1 signaling.
Zhou Y; Han Z; Zhao Z; Zhang J
Environ Toxicol; 2024 Feb; 39(2):562-571. PubMed ID: 37449671
[TBL] [Abstract] [Full Text] [Related]
9. A Syx-rhoa-Dia1 signaling axis regulates cell cycle progression, DNA damage, and therapy resistance in glioblastoma.
Lin WH; Feathers RW; Cooper LM; Lewis-Tuffin LJ; Chen J; Sarkaria JN; Anastasiadis PZ
JCI Insight; 2023 Jul; 8(13):. PubMed ID: 37427593
[TBL] [Abstract] [Full Text] [Related]
10. Integrative multiomics analysis identifies a metastasis-related gene signature and the potential oncogenic role of EZR in breast cancer.
Xiao G; Cheng F; Yuan J; Lu W; Wang P; Fan H
Oncol Res; 2022; 30(1):35-51. PubMed ID: 37304008
[TBL] [Abstract] [Full Text] [Related]
11. miR-3174 Is a New tumor Suppressor MicroRNA That Inhibits Several tumor-Promoting Genes in Glioblastoma.
Hanif F; Zhang Y; Dube C; Gibert MK; Saha S; Hudson K; Marcinkiewicz P; Kefas B; Guessous F; Abounader R
Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298284
[TBL] [Abstract] [Full Text] [Related]
12. Gibbs process distinguishes survival and reveals contact-inhibition genes in Glioblastoma multiforme.
Jahedi A; Kumar G; Kannan L; Agarwal T; Huse J; Bhat K; Kannan K
PLoS One; 2023; 18(2):e0277176. PubMed ID: 36795646
[TBL] [Abstract] [Full Text] [Related]
13. Factors affecting eye conservation and metastasis in posterior uveal melanomas.
Nalcı Baytaroğlu H; Gündüz AK; Mirzayev I; Özalp Ateş FS
Eur J Ophthalmol; 2023 Sep; 33(5):2024-2033. PubMed ID: 36762394
[TBL] [Abstract] [Full Text] [Related]
14. Infiltrating gliomas with FGFR alterations: Histologic features, genetic alterations, and potential clinical implications.
Dono A; El Achi H; Bundrant BE; Goli PS; Zhu P; Ozkizilkaya HI; Esquenazi Y; Ballester LY
Cancer Biomark; 2023; 36(2):117-131. PubMed ID: 36530080
[TBL] [Abstract] [Full Text] [Related]
15. Targeting ARHGEF12 promotes neuroblastoma differentiation, MYCN degradation, and reduces tumorigenicity.
Yang Y; Wang S; Cai J; Liang J; Zhang Y; Xie Y; Luo F; Tang J; Gao Y; Shen S; Feng H; Li Y
Cell Oncol (Dordr); 2023 Feb; 46(1):133-143. PubMed ID: 36520365
[TBL] [Abstract] [Full Text] [Related]
16. Rnd3 Is a Crucial Mediator of the Invasive Phenotype of Glioblastoma cells Downstream of Receptor Tyrosine Kinase Signalling.
Almarán B; Ramis G; Fernández de Mattos S; Villalonga P
Cells; 2022 Nov; 11(23):. PubMed ID: 36496976
[TBL] [Abstract] [Full Text] [Related]
17. YAP Activation in Promoting Negative Durotaxis and Acral Melanoma Progression.
Huang Y; Su J; Liu J; Yi X; Zhou F; Zhang J; Wang J; Meng X; Si L; Wu C
Cells; 2022 Nov; 11(22):. PubMed ID: 36428972
[TBL] [Abstract] [Full Text] [Related]
18. High-grade glioma imaging volumes and survival: a single-institution analysis of 101 patients after resection using intraoperative MRI.
Gamboa NT; Crabb B; Henson JC; Cole KL; Weaver BD; Karsy M; Jensen RL
J Neurooncol; 2022 Dec; 160(3):555-565. PubMed ID: 36394718
[TBL] [Abstract] [Full Text] [Related]
19. Anti‑tumor effects of anti‑epileptic drugs in malignant glioma cells.
Yagi C; Tatsuoka J; Sano E; Hanashima Y; Ozawa Y; Yoshimura S; Yamamuro S; Sumi K; Hara H; Katayama Y; Yoshino A
Oncol Rep; 2022 Dec; 48(6):. PubMed ID: 36281939
[TBL] [Abstract] [Full Text] [Related]
20. Baseline Serum Autoantibody Signatures Predict Recurrence and Toxicity in Melanoma Patients Receiving Adjuvant Immune Checkpoint Blockade.
Johannet P; Liu W; Fenyo D; Wind-Rotolo M; Krogsgaard M; Mehnert JM; Weber JS; Zhong J; Osman I
Clin Cancer Res; 2022 Sep; 28(18):4121-4130. PubMed ID: 36106402
[TBL] [Abstract] [Full Text] [Related]
[Next]
